Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached

Bibliographic Details
Main Author:	Massimo Breccia
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	EClinicalMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537020300213

Similar Items

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
by: Giuliana Alimena, et al.
Published: (2008-10-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016
by: Jimena Ylescas‐Soria, et al.
Published: (2019-06-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
by: Darlize Hübner Martins, et al.
Published: (2011-01-01)

Targeted treatment of chronic myeloid leukemia: role of imatinib
by: Ila Tamascar, et al.
Published: (2009-03-01)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01)

Neurological research and practice: the first milestone has been reached
by: Werner Hacke
Published: (2021-01-01)

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
by: Kibum Kim, et al.
Published: (2019-01-01)

DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA
by: Angela Dascalescu, et al.
Published: (2013-12-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival
by: Anthony A. Oyekunle, et al.
Published: (2016-06-01)

Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival
by: Anthony A. Oyekunle, et al.
Published: (2016-01-01)

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
by: Liu Delong, et al.
Published: (2008-10-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

A case of double leukemia: chronic myeloid leukemia intolerant to imatinib and chronic lymphocytic leukemia
by: Miriana Rocchi
Published: (2015-10-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Massimo Breccia, et al.
Published: (2011-05-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
by: Aamer Aleem
Published: (2009-04-01)

Melasma-like pigmentation during imatinib therapy for chronic myeloid leukemia
by: Suyash Singh Tomar, et al.
Published: (2020-01-01)

Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
by: Chen X, et al.
Published: (2020-06-01)

Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
by: Zheng Hu, et al.
Published: (2009-01-01)

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
by: Waclaw J, et al.
Published: (2015-09-01)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
by: Charles Chuah, et al.
Published: (2009-04-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
by: Roberta Bitencourt, et al.
Published: (2011-12-01)

Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
by: Pradeep Balasubramanian, et al.
Published: (2015-01-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
by: Ana Lucia Vieira-Mion, et al.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia
by: Neetu Pandey, et al.
Published: (2019-01-01)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
by: Katerina Arvaniti, et al.
Published: (2014-07-01)